FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Schilsky

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

United States

Occupations

Medical Oncology

Co-author Network

Publications

TOP 3
Rena M Conti; Meredith B Rosenthal; Richard L Schilsky; Victoria M Villaflor; Arielle C Bernstein; Peter B Bach
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.
Olwen M Hahn; Richard L Schilsky
Randomized controlled trials and comparative effectiveness research.
Richard L Schilsky
Targeted therapy for cancer: asking the right questions.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Schilsky (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Rena M Conti; Meredith B Rosenthal; Richard L Schilsky; Victoria M Villaflor; Arielle C Bernstein; Peter B Bach
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(9):1134-9.
2012: Olwen M Hahn; Richard L Schilsky
Randomized controlled trials and comparative effectiveness research.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(34):4194-201.
2012: Richard L Schilsky
Targeted therapy for cancer: asking the right questions.
Oncology (Williston Park, N.Y.) 2012;26(10):947-9.
2012: Richard L Schilsky
Scarcity of vital oncology drugs: finding long-term solutions.
Clinical advances in hematology & oncology : H&O 2012;10(9):597-9.
2012: Manish R Sharma; Richard L Schilsky
Role of randomized phase III trials in an era of effective targeted therapies.
Nature reviews. Clinical oncology 2012;9(4):208-14.
2012: Federico Innocenti; Chen Jiang; Hedy L Kindler; Michiaki Kubo; Liang Li; Howard L McLeod; Taisei Mushiroda; Yusuke Nakamura; Kouros Owzar; Nancy L Cox; Patrick Evans; Paula Friedman; Kathleen M Giacomini; Dylan Glubb; Richard M Goldberg; Donna Hollis; Herbert Hurwitz; Richard L Schilsky; Liewei Wang; Hitoshi Zembutsu; Mark J Ratain
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(2):577-84.
2011: Laurie Fenton Ambrose; Kenneth Buetow; Jamie Freedman; Stephen Friend; Richard L Schilsky
Using patient-initiated study participation in the development of evidence for personalized cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(21):6651-7.
2011: Michael L Maitland; Richard L Schilsky
Clinical trials in the era of personalized oncology.
CA: a cancer journal for clinicians 2011;61(6):365-81.
2011: Richard L Schilsky; Mark Crowther
Update in hematology and oncology: evidence published in 2010.
Annals of internal medicine 2011;154(7):487-94.
2011: Richard L Schilsky
Tumor heterogeneity as the foundation of personalized cancer treatment.
Seminars in oncology 2011;38(2):171-2.
2011: Richard L Schilsky
Accrual to cancer clinical trials in the era of molecular medicine.
Science translational medicine 2011;3(75):75cm9.
2011: Ezra E W Cohen; Richard L Schilsky
The next phase of chemoprevention research.
Cancer prevention research (Philadelphia, Pa.) 2011;4(3):293-5.
2011: Manish R Sharma; Richard L Schilsky
GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy.
Nature reviews. Clinical oncology 2011;8(2):70-2.
2010: Lee D Kaiser; Allen S Melemed; Alaknanda J Preston; Hilary A Chaudri-Ross; Donna Niedzwiecki; Gwendolyn A Fyfe; Jacqueline M Gough; William D Bushnell; Cynthia L Stephens; M Kelsey Mace; Jeffrey S Abrams; Richard L Schilsky
Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(34):5046-53.
2010: Andrew N Freedman; Leah B Sansbury; William D Figg; Arnold L Potosky; Sheila Weiss Smith; Muin J Khoury; Stefanie A Nelson; Richard M Weinshilboum; Mark J Ratain; Howard L McLeod; Robert S Epstein; Geoffrey S Ginsburg; Richard L Schilsky; Geoffrey Liu; David A Flockhart; Cornelia M Ulrich; Robert L Davis; Lawrence J Lesko; Issam Zineh; Gurvaneet Randhawa; Christine B Ambrosone; Mary V Relling; Nat Rothman; Heng Xie; Margaret R Spitz; Rachel Ballard-Barbash; James H Doroshow; Lori M Minasian
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
Journal of the National Cancer Institute 2010;102(22):1698-705.
2010: Hedy L Kindler; Donna Niedzwiecki; Donna Hollis; Susan Sutherland; Deborah Schrag; Herbert Hurwitz; Federico Innocenti; Mary Frances Mulcahy; Eileen O'Reilly; Timothy F Wozniak; Joel Picus; Pankaj Bhargava; Robert J Mayer; Richard L Schilsky; Richard M Goldberg
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(22):3617-22.
2010: Tara Gangadhar; Richard L Schilsky
Molecular markers to individualize adjuvant therapy for colon cancer.
Nature reviews. Clinical oncology 2010;7(6):318-25.
2010: Richard L Schilsky
Personalized medicine in oncology: the future is now.
Nature reviews. Drug discovery 2010;9(5):363-6.
2010: David G Menter; Richard L Schilsky; Raymond DuBois
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1384-90.
2010: Richard L Schilsky; Jeff Allen; Joshua Benner; Ellen Sigal; Mark McClellan
Commentary: tackling the challenges of developing targeted therapies for cancer.
The oncologist 2010;15(5):484-7.
2009: Richard L Schilsky
Personalizing cancer care: American Society of Clinical Oncology presidential address 2009.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(23):3725-30.
2008: Gary M Strauss; James E Herndon; Michael A Maddaus; David W Johnstone; Elizabeth A Johnson; David H Harpole; Heidi H Gillenwater; Dorothy M Watson; David J Sugarbaker; Richard L Schilsky; Everett E Vokes; Mark R Green
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(31):5043-51.
2008: Mark R Green; Stephen L George; Richard L Schilsky
Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.
Seminars in oncology 2008;35(5):470-83.
2008: Michael C Perry; Robert L Comis; Richard L Schilsky
Introduction: contributions of the cooperative groups.
Seminars in oncology 2008;35(5):459.
2008: Richard L Schilsky; Gary Gordon; Tona M Gilmer; Sara A Courtneidge; Lynn M Matrisian; Oren Grad; William G Nelson
The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics).
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5685-91.
2008: Richard L Schilsky
How not to treat cancer.
The lancet oncology 2008;9(6):504-5.
2008: Robin Zon; Neal J Meropol; Robert B Catalano; Richard L Schilsky
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(15):2562-7.
2008: Christopher K Daugherty; Mark J Ratain; Ezekiel J Emanuel; Ann T Farrell; Richard L Schilsky
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1371-8.
2008: Elizabeth B Lamont; James E Herndon; Jane C Weeks; I Craig Henderson; Rogerio Lilenbaum; Richard L Schilsky; Nicholas A Christakis
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
Medical care 2008;46(3):303-8.
2008: Julie R Gralow; Robert F Ozols; Dean F Bajorin; Bruce D Cheson; Howard M Sandler; Eric P Winer; James Bonner; George D Demetri; Walter Curran; Patricia Anne Ganz; Barnett S Kramer; Mark G Kris; Maurie Markman; Robert J Mayer; Derek Raghavan; Scott Ramsey; Gregory H Reaman; Raymond Sawaya; Lynn Schuchter; John W Sweetenham; Linda Vahdat; Nancy E Davidson; Richard L Schilsky; Allen S Lichter
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):313-25.
2008: Mitchell C Posner; Donna Niedzwiecki; Alan P Venook; Donna R Hollis; Hedy L Kindler; Edward W Martin; Richard L Schilsky; Richard M Goldberg; Robert J Mayer
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
Annals of surgical oncology 2008;15(1):158-64.
2007: Wei Peng Yong; Apurva A Desai; Federico Innocenti; Jacqueline Ramirez; Dale R Shepard; Ken Kobayashi; Larry House; Gini F Fleming; Nicholas J Vogelzang; Richard L Schilsky; Mark J Ratain
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2007;60(6):811-9.
2007: Robert C Young; Michael A Friedman; Richard L Schilsky; Ellen V Sigal
Drug safety and drug efficacy: two sides of the same coin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2533-4.
2007: Richard L Schilsky
Target practice: oncology drug development in the era of genomic medicine.
Clinical trials (London, England) 2007;4(2):163-6; discussion 173-7.
2007: Ann M Mauer; Elizabeth S Rich; Richard L Schilsky
The role of cooperative groups in cancer clinical trials.
Cancer treatment and research 2007;132():111-29.
2007: Robert F Ozols; Roy S Herbst; Yolonda L Colson; Julie R Gralow; James Bonner; Walter Curran; Burton L Eisenberg; Patricia Anne Ganz; Barnett S Kramer; Mark G Kris; Maurie Markman; Robert J Mayer; Derek Raghavan; Gregory H Reaman; Raymond Sawaya; Richard L Schilsky; Lynn Schuchter; John W Sweetenham; Linda Vahdat; Rodger J Winn
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):146-62.
2006: Andrea K Bial; Richard L Schilsky; Greg A. Sachs
Evaluation of cognition in cancer patients: special focus on the elderly.
Critical reviews in oncology/hematology 2006;60(3):242-55.
2006: David M Dilts; Alan B Sandler; Matthew Baker; Steven K Cheng; Stephen L George; Kathleen S Karas; Stephen McGuire; Gourija S Menon; Jason Reusch; Debbie Sawyer; Maren Scoggins; Amy Wu; Kai Zhou; Richard L Schilsky
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(28):4553-7.
2006: Elizabeth B Lamont; James E Herndon; Jane C Weeks; I Craig Henderson; Craig C Earle; Richard L Schilsky; Nicholas A Christakis
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).
Journal of the National Cancer Institute 2006;98(18):1335-8.
2006: Jeffrey A Meyerhardt; Denise Heseltine; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; James P Thomas; Heidi Nelson; Renaud Whittom; Alexander Hantel; Richard L Schilsky; Charlie S Fuchs
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3535-41.
2006: Mark J Ratain; Antonius A Miller; howard mcleod; Alan P Venook; Merrill J Egorin; Richard L Schilsky
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 2):3612s-6s.
2006: Richard L Schilsky; O Ross McIntyre; James F Holland; Emil Frei
A concise history of the cancer and leukemia group B.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 2):3553s-5s.
2006: Gregory Friberg; Richard L Schilsky
Is oral tegafur with leucovorin equivalent to intravenous 5-fluorouracil and leucovorin in colorectal cancer?
Nature clinical practice. Oncology 2006;3(5):240-1.
2006: FREDERICK HAUSHEER; Richard L Schilsky; Stacey Bain; Elmer J Berghorn; Frank Lieberman
Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.
Seminars in oncology 2006;33(1):15-49.
2005: Elizabeth B Lamont; James E Herndon; Jane C Weeks; I Craig Henderson; Rogerio Lilenbaum; Richard L Schilsky; Nicholas A Christakis
Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.
Journal of the National Cancer Institute 2005;97(14):1080-3.
2005: Apurva A Desai; Richard L Schilsky; A Young; Linda Janisch; Walter M Stadler; Nicholas J Vogelzang; S Cadden; J A Wright; Mark J Ratain
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(6):958-65.
2005: Gary J Kelloff; John M Hoffman; Bruce Johnson; Howard I Scher; Barry A Siegel; Edward Y Cheng; Bruce D Cheson; Joyce A O'Shaughnessy; Kathryn Z Guyton; David A Mankoff; Lalitha K Shankar; Steven M Larson; Caroline C Sigman; Richard L Schilsky; Daniel C Sullivan
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(8):2785-808.
2004: Richard L Schilsky
First-line treatment options for patients with metastatic colorectal cancer.
Nature clinical practice. Oncology 2004;1(2):70-1.
2004: Richard M Goldberg; Alan P Venook; Richard L Schilsky
Cetuximab in the treatment of colorectal cancer.
Clinical advances in hematology & oncology : H&O 2004;2(11):1-10; quiz 11-12.
2004: Federico Innocenti; Samir D Undevia; Jacqueline Ramírez; Sridhar Mani; Richard L Schilsky; Nicholas J Vogelzang; Marisol Prado; Mark J Ratain
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
Clinical pharmacology and therapeutics 2004;76(5):490-502.
2004: Samir D Undevia; Hedy L Kindler; Linda Janisch; S C Olson; Richard L Schilsky; Nicholas J Vogelzang; K A Kimmel; T A Macek; Mark J Ratain
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(11):1705-11.
2004: Paul R Helft; Richard L Schilsky; Frank J Hoke; Daphne Williams; Hedy L Kindler; Evie Sprague; Mark DeWitte; Helen K Martino; John Erickson; Lini Pandite; Mark Russo; John M Lambert; Maria Howard; Mark J Ratain
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4363-8.
2004: Sheila E Taube; Massimo Gion; Richard L Schilsky
3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice.
Expert review of molecular diagnostics 2004;4(4):431-3.
2004: Gary J Kelloff; Richard L Schilsky; David S Alberts; Robert W Day; Kathryn Z Guyton; Homer L Pearce; Jonathan C Peck; Robert Phillips; Caroline C Sigman
Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3908-18.
2004: Gary J Kelloff; Robert C Bast; Donald S Coffey; Anthony V D'Amico; Robert S Kerbel; John W Park; Raymond W Ruddon; Gordon J S Rustin; Richard L Schilsky; Caroline C Sigman; George Vande Woude
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3881-4.
2004: Ann H Partridge; Nadia Hackett; Emily Blood; Rebecca Gelman; Steven Joffe; Susan Bauer-Wu; Katherine Knudsen; Karen M Emmons; Deborah Collyar; Richard L Schilsky; Eric P Winer
Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants.
Journal of the National Cancer Institute 2004;96(8):629-32.
2003: Richard L Schilsky
Are targeted therapies really targeted?
Clinical advances in hematology & oncology : H&O 2003;1(12):722-3.
2003: Richard L Schilsky
Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(20):3718-20.
2003: Gini F Fleming; Richard L Schilsky; L Philip Schumm; A Meyerson; A M Hong; Nicholas J Vogelzang; Mark J Ratain
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(7):1142-7.
2003: Michael B Sawyer; Mark J Ratain; Donna Bertucci; Robert P Smith; Richard L Schilsky; Nicholas J Vogelzang; Keith Shulman; Edwin C Douglass; Gini F Fleming
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1859-65.
2002: Gini F Fleming; Neal J Meropol; Gary Rosner; Donna Hollis; William E Carson; Michael Caligiuri; Joanne Mortimer; Katherine Tkaczuk; Robin Parihar; Richard L Schilsky; Mark J Ratain
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3718-27.
2002: Richard L Schilsky; Sheila E Taube
Tumor markers as clinical cancer tests--are we there yet?
Seminars in oncology 2002;29(3):211-2.
2002: Richard L Schilsky
Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation.
Clinical colorectal cancer 2002;2(1):51-2.
2002: Richard L Schilsky; Lynn M Dressler; Donna Bucci; Laura Monovich; Scott Jewell; Saul Suster; Michael A Caligiuri; Philip W Kantoff; Carolyn Corlies Compton
Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):943-8.
2002: Dale R Shepard; Sridhar Mani; Helen Kastrissios; Susan Learned-Coughlin; Deborah Smith; Phillip Ertel; Steve Magnum; Linda Janisch; Gini F Fleming; Richard L Schilsky; Mark J Ratain
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
Cancer chemotherapy and pharmacology 2002;49(5):398-402.
2002: Richard L Schilsky
End points in cancer clinical trials and the drug approval process.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):935-8.
2002: Richard L Schilsky; Jeremey Levin; William H West; Alfred Wong; Bruce Colwell; Michael P Thirlwell; Rafat H Ansari; William N Bell; Robin L White; Barbara B Yates; Paul V McGuirt; Richard Pazdur
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1519-26.
2002: Elizabeth B Lamont; Diane S Lauderdale; Richard L Schilsky; Nicholas A Christakis
Construct validity of medicare chemotherapy claims: the case of 5FU.
Medical care 2002;40(3):201-11.
2002: Richard L Schilsky; Donna Bertucci; Nicholas J Vogelzang; Hedy L Kindler; Mark J Ratain
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(2):582-7.
2002: M Eileen Dolan; Richard L Schilsky
Silence is golden: gene hypermethylation and survival in large-cell lymphoma.
Journal of the National Cancer Institute 2002;94(1):6-7.
2002: Lalitha Iyer; Soma Das; Linda Janisch; M Wen; Jacqueline Ramírez; Theodore Karrison; Gini F Fleming; Everett E Vokes; Richard L Schilsky; Mark J Ratain
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
The pharmacogenomics journal 2002;2(1):43-7.
2002: Charles D Blanke; J Shultz; J Cox; M Modiano; R Isaacs; B Kasimis; Richard L Schilsky; J Fleagle; M Moore; Nancy Kemeny; David A Carlin; Luz D Hammershaimb; D Haller
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(1):87-91.
2001: Sridhar Mani; Nicholas J Vogelzang; Donna Bertucci; Walter M Stadler; Richard L Schilsky; Mark J Ratain
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Cancer 2001;92(6):1567-76.
2001: C Eng; Hedy L Kindler; Richard L Schilsky
Oral fluoropyrimidine treatment of colorectal cancer.
Clinical colorectal cancer 2001;1(2):95-103.
2001: Reginald Ewesuedo; Lalitha Iyer; Soma Das; A Koenig; Sridhar Mani; Nicholas J Vogelzang; Richard L Schilsky; W Brenckman; Mark J Ratain
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2084-90.
2001: B C Goh; Mark J Ratain; Donna Bertucci; R Smith; Sridhar Mani; Nicholas J Vogelzang; Richard L Schilsky; M Hutchison; M Smith; Steven Averbuch; E Douglass
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1476-84.
2000: Stephanie F Williams; Richard L Schilsky
Antineoplastic drugs administered during pregnancy.
Seminars in oncology 2000;27(6):618-22.
2000: Richard L Schilsky
Pharmacology and clinical status of capecitabine.
Oncology (Williston Park, N.Y.) 2000;14(9):1297-306; discussion 1309-11.
2000: Richard L Schilsky; M Eileen Dolan; Donna Bertucci; Reginald Ewesuedo; Nicholas J Vogelzang; Sridhar Mani; Lynette R Wilson; Mark J Ratain
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3025-31.
2000: Sridhar Mani; H Hochster; T Beck; E M Chevlen; M A O'Rourke; C H Weaver; W N Bell; R White; C McGuirt; Jeremey Levin; JA Hohneker; Richard L Schilsky; J Lokich
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(15):2894-901.
2000: Richard L Schilsky; H L Kindler
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Expert opinion on investigational drugs 2000;9(7):1635-49.
2000: Richard L Schilsky; R Bukowski; Howard A Burris; H Hochster; M O'Rourke; J G Wall; Sridhar Mani; T Bonny; Jeremey Levin; JA Hohneker
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(4):415-20.
1999: Elizabeth B Lamont; Richard L Schilsky
The oral fluoropyrimidines in cancer chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2289-96.
1999: AM Storniolo; N H Enas; C A Brown; M Voi; Mace L Rothenberg; Richard L Schilsky
An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.
Cancer 1999;85(6):1261-8.
1999: Sridhar Mani; David F Sciortino; Brian L Samuels; R Arrietta; Richard L Schilsky; Everett E Vokes; S Benner
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma.
Investigational new drugs 1999;17(1):97-101.
1998: Richard L Schilsky
Biochemical and clinical pharmacology of 5-fluorouracil.
Oncology (Williston Park, N.Y.) 1998;12(10 Suppl 7):13-8.
1998: Rogerio Lilenbaum; Antonius A Miller; G Batist; Stephen A Bernard; Donna Hollis; Gary Rosner; Merrill J Egorin; Richard L Schilsky; M J Ratain
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3302-9.
1998: Sridhar Mani; John W Kugler; David F Sciortino; JC Garcia; Rafat H Ansari; Rod A Humerickhouse; Fabrizio Michelassi; Mitchell C Posner; KL Shulman; Richard L Schilsky; Marcy A List; Everett E Vokes; S Benner
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(9):1035-7.
1998: M Eileen Dolan; S K Roy; AA Fasanmade; P R Paras; Richard L Schilsky; Mark J Ratain
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1803-10.
1998: Nicholas J Vogelzang; Sridhar Mani; Richard L Schilsky; Rafat H Ansari; David A Taber; S N Rhinehart; JC Garcia; S C Meyer; R Mick; Bruce E Brockstein; Walter M Stadler; Mark J Ratain; Everett E Vokes
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(4):929-34.
1998: Richard L Schilsky; JA Hohneker; Mark J Ratain; Linda Janisch; Leslie Ann Smetzer; V S Lucas; SP Khor; R Diasio; Daniel Von Hoff; Howard A Burris
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1450-7.
1998: Sridhar Mani; John W Kugler; James A Knost; David F Sciortino; J Gibbons; JC Garcia; Rafat H Ansari; Richard L Schilsky; Everett E Vokes
Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer.
Investigational new drugs 1998;16(3):275-8.
1998: Sridhar Mani; Lalitha Iyer; Linda Janisch; X Wang; Gini F Fleming; Richard L Schilsky; Mark J Ratain
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
Cancer chemotherapy and pharmacology 1998;42(1):84-7.
1997: Mark J Ratain; L A Skoog; S M O'Brien; N Cooper; Richard L Schilsky; Nicholas J Vogelzang; M Gerber; P K Narang; S J Nicol
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(8):807-9.
1997: Antonius A Miller; Gary Rosner; M J Ratain; Donna Hollis; M R Green; Richard L Schilsky
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):719-25.
1997: Gini F Fleming; S M O'Brien; Philip C Hoffman; Everett E Vokes; Nicholas J Vogelzang; Richard L Schilsky; S E Waggoner; Mark J Ratain
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
Cancer chemotherapy and pharmacology 1997;39(3):227-32.
1996: Gary Rosner; J B Hargis; Donna Hollis; D R Budman; R B Weiss; I C Henderson; Richard L Schilsky
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(11):3000-8.
1996: Antonius A Miller; R C Lilenbaum; Thomas J Lynch; Gary Rosner; M J Ratain; M R Green; Richard L Schilsky
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1964-5.
1996: R Mick; Everett E Vokes; T M Lestingi; W Gray-Stern; Gini F Fleming; Richard L Schilsky; Mark J Ratain
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
Clinical pharmacology and therapeutics 1996;59(3):349-59.
1996: Mark J Ratain; R Mick; Linda Janisch; F Berezin; Richard L Schilsky; Nicholas J Vogelzang; M Kut
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Pharmacogenetics 1996;6(1):93-101.
1996: Richard L Schilsky
Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era.
Stem cells (Dayton, Ohio) 1996;14(1):29-32.
1995: K Shulman; Richard L Schilsky
Adjuvant therapy of colon cancer.
Seminars in oncology 1995;22(6):600-10.
1995: R C Lilenbaum; M J Ratain; Antonius A Miller; J B Hargis; Donna Hollis; Gary Rosner; S M O'Brien; L Brewster; M R Green; Richard L Schilsky
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2230-7.
1995: Mark J Ratain; Gary Rosner; S L Allen; M Costanza; David A Van Echo; I C Henderson; Richard L Schilsky
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):741-7.
1994: Antonius A Miller; J B Hargis; R C Lilenbaum; S Z Fields; Gary Rosner; Richard L Schilsky
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(12):2743-50.
1994: Linda Janisch; R Mick; Richard L Schilsky; Nicholas J Vogelzang; S O'Brien; M Kut; Mark J Ratain
Prognostic factors for survival in patients treated in phase I clinical trials.
Cancer 1994;74(7):1965-73.
1994: K Kobayashi; Nicholas J Vogelzang; S M O'Brien; Richard L Schilsky; Everett E Vokes; Mark J Ratain
A phase I study of intermittent infusion cladribine in patients with solid tumors.
Cancer 1994;74(1):168-73.
1994: Gini F Fleming; Mark J Ratain; S M O'Brien; Richard L Schilsky; Philip C Hoffman; J M Richards; Nicholas J Vogelzang; D A Kasunic; R H Earhart
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
Journal of the National Cancer Institute 1994;86(5):368-72.
1994: Nicholas J Vogelzang; R Mick; Linda Janisch; F Berezin; Richard L Schilsky; Mark J Ratain
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Cancer research 1994;54(1):114-9.
1994: R B Mitchell; M Eileen Dolan; Linda Janisch; Nicholas J Vogelzang; Mark J Ratain; Richard L Schilsky
Sequential therapy with dacarbazine and carmustine: a phase I study.
Cancer chemotherapy and pharmacology 1994;34(6):509-14.
1993: Mark J Ratain; R Mick; Richard L Schilsky; Mark Siegler
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
Journal of the National Cancer Institute 1993;85(20):1637-43.
1993: Brian L Samuels; R Mick; Nicholas J Vogelzang; Stephanie F Williams; Richard L Schilsky; Ahmad R Safa; S M O'Brien; Mark J Ratain
Modulation of vinblastine resistance with cyclosporine: a phase I study.
Clinical pharmacology and therapeutics 1993;54(4):421-9.
1993: Everett E Vokes; M E Dolan; S Krishnasamy; R Mick; Mark J Ratain; F Berezin; D Brachman; G Whitman; Richard L Schilsky; J Charette
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(7):591-5.
1993: Mark J Ratain; R Mick; F Berezin; Linda Janisch; Richard L Schilsky; Nicholas J Vogelzang; L B Lane
Phase I study of amonafide dosing based on acetylator phenotype.
Cancer research 1993;53(10 Suppl):2304-8.
1993: K Kobayashi; Richard L Schilsky
Update on biochemical modulation of chemotherapeutic agents.
Oncology (Williston Park, N.Y.) 1993;7(5):99-106, 109; discussion 110-4, 117.
1993: Richard L Schilsky; Linda Janisch; F Berezin; R Mick; Nicholas J Vogelzang; Mark J Ratain
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
Cancer research 1993;53(6):1293-6.
1993: Richard L Schilsky; Mark J Ratain; Linda Janisch; Nicholas J Vogelzang; V S Lucas; J Ravitch; JA Hohneker; N J Clendeninn; R L Tuttle
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
Cancer chemotherapy and pharmacology 1993;31(4):283-8.
1993: Everett E Vokes; S M O'Brien; Nicholas J Vogelzang; Richard L Schilsky; Mark J Ratain
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
Cancer chemotherapy and pharmacology 1993;32(5):347-52.
1992: Gini F Fleming; Richard L Schilsky
Antifolates: the next generation.
Seminars in oncology 1992;19(6):707-19.
1992: S E Myers; Richard L Schilsky
Prospects for fertility after cancer chemotherapy.
Seminars in oncology 1992;19(5):597-604.
1992: Richard L Schilsky
Biochemical pharmacology of chemotherapeutic drugs used as radiation enhancers.
Seminars in oncology 1992;19(4 Suppl 11):2-7.
1992: Richard L Schilsky; Mark J Ratain; Everett E Vokes; Nicholas J Vogelzang; J Anderson; B A Peterson
Laboratory and clinical studies of biochemical modulation by hydroxyurea.
Seminars in oncology 1992;19(3 Suppl 9):84-9.
1992: Everett E Vokes; Daniel J Haraf; WR Panje; Richard L Schilsky; Ralph R Weichselbaum
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
Seminars in oncology 1992;19(3 Suppl 9):53-8.
1991: Mark J Ratain; R Mick; F Berezin; Linda Janisch; Richard L Schilsky; Stephanie F Williams; J Smiddy
Paradoxical relationship between acetylator phenotype and amonafide toxicity.
Clinical pharmacology and therapeutics 1991;50(5 Pt 1):573-9.
1991: Mark J Ratain; R Mick; Richard L Schilsky; Nicholas J Vogelzang; F Berezin
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(8):1480-6.
1991: W Gradishar; Everett E Vokes; Richard L Schilsky; R Weichselbaum; WR Panje
Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience.
Medical and pediatric oncology 1991;19(1):8-15.
1991: Everett E Vokes; J W Raschko; Nicholas J Vogelzang; E E Warfield; Mark J Ratain; James Doroshow; Richard L Schilsky
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
Cancer chemotherapy and pharmacology 1991;28(1):69-73.
1990: Richard L Schilsky; K E Choi; J Grayhack; D Grimmer; C Guarnieri; L Fullem
Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(12):2054-61.
1990: Mark J Ratain; Richard L Schilsky; BA Conley; Merrill J Egorin
Pharmacodynamics in cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(10):1739-53.
1990: Richard L Schilsky; Mark J Ratain
Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration.
Journal of the National Cancer Institute 1990;82(17):1411-5.
1990: Everett E Vokes; Richard L Schilsky; Ralph R Weichselbaum; Mark F. Kozloff; WR Panje
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(2):241-7.
1990: P P Lee; Richard L Schilsky
Inhibition of thymidylate synthase by the diastereoisomers of leucovorin.
Cancer chemotherapy and pharmacology 1990;26(4):273-7.
1989: W J Gradishar; Richard L Schilsky
Ovarian function following radiation and chemotherapy for cancer.
Seminars in oncology 1989;16(5):425-36.
1989: Everett E Vokes; WR Panje; Richard L Schilsky; R Mick; Azhar M. Awan; W J Moran; M D Goldman; A G Tybor; Ralph R Weichselbaum
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(6):761-8.
1989: Everett E Vokes; Richard L Schilsky; Ralph R Weichselbaum; A Guaspari; C M Guarnieri; S M Whaling; WR Panje
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
Cancer 1989;63(6 Suppl):1048-53.
1989: Richard L Schilsky; K E Choi; Everett E Vokes; A Guaspari; C Guarnieri; S Whaling; M A Liebner
Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing.
Cancer 1989;63(6 Suppl):1018-21.
1989: Mark J Ratain; Richard L Schilsky; K E Choi; C Guarnieri; D Grimmer; Nicholas J Vogelzang; E Senekjian; M A Liebner
Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.
Clinical pharmacology and therapeutics 1989;45(3):226-33.
1989: Richard L Schilsky
Male fertility following cancer chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(3):295-7.
1989: Everett E Vokes; Richard L Schilsky; K E Choi; D M Magid; C M Guarnieri; S M Whaling; Mark J Ratain; Ralph R Weichselbaum; WR Panje
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
Cancer 1989;63(1):30-6.
1989: D M Magid; Everett E Vokes; Richard L Schilsky; C M Guarnieri; S M Whaling; Ralph R Weichselbaum; WR Panje
A randomized study of inpatient versus outpatient continuous intravenous infusion chemotherapy: psychosocial aspects.
Selective cancer therapeutics 1989;5(3):137-45.
1988: Mark J Ratain; Richard L Schilsky; B R Wojack; T Simon; E K Senekjian; Nicholas J Vogelzang
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.
Journal of the National Cancer Institute 1988;80(17):1412-6.
1988: S P Ackland; Richard L Schilsky; Michael A Beckett; Ralph R Weichselbaum
Synergistic cytotoxicity and DNA strand break formation by bromodeoxyuridine and bleomycin in human tumor cells.
Cancer research 1988;48(15):4244-9.
1988: Mark J Ratain; A E Staubus; Richard L Schilsky; L Malspeis
Limited sampling models for amonafide (NSC 308847) pharmacokinetics.
Cancer research 1988;48(14):4127-30.
1988: Everett E Vokes; K E Choi; Richard L Schilsky; W J Moran; C M Guarnieri; Ralph R Weichselbaum; WR Panje
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(4):618-26.
1988: Everett E Vokes; WR Panje; Ralph R Weichselbaum; Richard L Schilsky; W J Moran; Azhar M. Awan; C M Guarnieri
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 1988;98(4):295-8.
1988: K E Choi; Richard L Schilsky
Resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate by chiral high-performance liquid chromatography.
Analytical biochemistry 1988;168(2):398-404.
1988: Everett E Vokes; W J Moran; Azhar M. Awan; Richard L Schilsky; M Goldman; H G Sutton; Ralph R Weichselbaum; WR Panje
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer.
NCI monographs : a publication of the National Cancer Institute 1988;(6):353-6.
1987: S P Ackland; Richard L Schilsky
High-dose methotrexate: a critical reappraisal.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(12):2017-31.
1987: Charles L Bennett; J A Sinkule; Richard L Schilsky; E Senekjian; K E Choi
Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
Cancer research 1987;47(7):1952-6.